Journal article
Dominant-negative mutations in human IL6ST underlie hyper-IgE syndrome
- Abstract:
- Autosomal dominant hyper-IgE syndrome (AD-HIES) is typically caused by dominant-negative (DN) STAT3 mutations. Patients suffer from cold staphylococcal lesions and mucocutaneous candidiasis, severe allergy, and skeletal abnormalities. We report 12 patients from 8 unrelated kindreds with AD-HIES due to DN IL6ST mutations. We identified seven different truncating mutations, one of which was recurrent. The mutant alleles encode GP130 receptors bearing the transmembrane domain but lacking both the recycling motif and all four STAT3-recruiting tyrosine residues. Upon overexpression, the mutant proteins accumulate at the cell surface and are loss of function and DN for cellular responses to IL-6, IL-11, LIF, and OSM. Moreover, the patients’ heterozygous leukocytes and fibroblasts respond poorly to IL-6 and IL-11. Consistently, patients with STAT3 and IL6ST mutations display infectious and allergic manifestations of IL-6R deficiency, and some of the skeletal abnormalities of IL-11R deficiency. DN STAT3 and IL6ST mutations thus appear to underlie clinical phenocopies through impairment of the IL-6 and IL-11 response pathways.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, 7.5MB, Terms of use)
-
- Publisher copy:
- 10.1084/jem.20191804
- Publisher:
- Rockefeller University Press
- Journal:
- Journal of Experimental Medicine More from this journal
- Volume:
- 217
- Issue:
- 6
- Article number:
- e20191804
- Place of publication:
- United States
- Publication date:
- 2020-03-24
- Acceptance date:
- 2020-02-18
- DOI:
- EISSN:
-
1540-9538
- ISSN:
-
0022-1007
- Pmid:
-
32207811
- Language:
-
English
- Keywords:
- Pubs id:
-
1096594
- Local pid:
-
pubs:1096594
- Deposit date:
-
2020-05-22
Terms of use
- Copyright holder:
- Beziat et al.
- Copyright date:
- 2020
- Rights statement:
- © 2020 Beziat et al. This article is distributed under the terms of an Attribution ´ –Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license.
If you are the owner of this record, you can report an update to it here: Report update to this record